Isomorphic Labs closes $5B Series C to move drug candidates toward trials
TechCrunch AI · rss · 2026-11-17
Isomorphic Labs, the AI drug-discovery platform spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C round as it looks to advance drug candidates into clinical trials. Same event as The Decoder's report; the company has no approved drugs yet.
More from Venture
- SF's AI boom could mint $1.2 trillion; average OpenAI insider stake near $126M — bloomberg · 2026-11-17
- VC's 'Diffusion Gap' formula: lab revenue growth minus log-linear CapEx spend — saranormous · 2026-11-17
- Voyage Labs raises $12M for a specialized AI travel planning agent — TechCrunch AI · 2026-11-17
- HSBC dumps $300M of Oracle/OpenAI data center debt at steep mid-80s discount — GaryMarcus · 2026-11-17
- Isomorphic Labs raises $5B, its second mega-round in six months — The Decoder · 2026-11-17
- Anthropic IPO allocation will disappoint sellers cashing out early, investor warns — firstadopter · 2026-11-17